Boston, MA -- (SBWIRE) -- 09/06/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Spectrum Pharmaceuticals, Inc.(NASDAQ:SPPI), MiMedx Group Inc (NASDAQ:MDXG), Dyax Corp. (NASDAQ:DYAX), Santarus, Inc. (NASDAQ:SNTS)
Spectrum Pharmaceuticals, Inc.(NASDAQ:SPPI) shares increased 9.83% to $8.10. The company on Sept. 3 announced the launch of Marqibo. The company also confirmed the shipment of its first commercial orders for Marqibo. Marqibo is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine.
Additionally, the company on August 7 announced financial results for the three-month period ended June 30, 2013. The Company recorded net loss of $10.2 million, or ($0.17) per basic and diluted share in the three-month period ended June 30, 2013, compared to a net income of $18.1 million, or $0.31 per basic and $0.29 per diluted share in the comparable period in 2012.
How Should Investors Trade SPPI After The Recent Volatility? Get Free Report Here
MiMedx Group Inc (NASDAQ:MDXG) stock jumped 19.77% to $4.61. The Rosen Law Firm, P.A. on Sept. 4 announces that it is investigating potential securities claims against MiMedx Group, Inc. (NASDAQ:MDXG) resulting from reports that the FDA notified the Company that it is unlawfully manufacturing drugs at one of its plants.
The Rosen Law Firm is preparing a securities class action lawsuit on behalf of MiMedx investors to recover investors' losses. If you purchased or acquired MiMedx on or before September 4, 2013, please go to the website at http://rosenlegal.com for more information.
How Should Investors Trade MDXG After The Recent Volatility? Get Free Report Here
Dyax Corp. (NASDAQ:DYAX) shares increased 7.14% to $5.10. The company on August 15 announced dosing of the first subject in a Phase 1 clinical study evaluating the safety and tolerability of single subcutaneous administration of DX-2930, its fully human monoclonal antibody inhibitor of plasma kallikrein. Dyax, a biopharmaceutical company focused on hereditary angioedema (HAE) and other plasma kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks. DX-2930 was discovered using Dyax’s proprietary phage display technology platform.
Additionally, the company will participate in the Morgan Stanley Global Healthcare Conference, being held September 9-11, 2013 at the Grand Hyatt in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will participate in a fireside chat to discuss the Company’s key value drivers on Wednesday, September 11 at 10:00 AM (ET).
Is DYAX A Good Buy After The Recent Price Movement? Find Out Here
Santarus, Inc. (NASDAQ:SNTS) stock decreased 2.14% to $22.89. The company announced that Gerald T. Proehl, president and chief executive officer, will make presentations at the following investment conferences: Morgan Stanley Global Healthcare Conference on September 10, 2013, at 3:30 p.m. Eastern time (12:30 p.m. Pacific time) in New York City, and Stifel Nicolaus Healthcare Conference on September 11, 2013, at 2:05 p.m. Eastern time (11:05 a.m. Pacific time) in Boston.
Is SNTS A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaime
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)